+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Sympathectomy inhibits growth of a murine plasmacytoma tumor

Sympathectomy inhibits growth of a murine plasmacytoma tumor

Journal of the Autonomic Nervous System 13(2): 149-160

The effects of 6-hydroxydopamine (6-OHDA), N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) and anti-nerve growth factor (anti-NGF) on the development and growth of a tumor of non-neuronal origin were studied in mice. Murine LPC-1 plasmacytoma cells were grown either s.c. as solid tumors in the hindleg or i.p. in ascitic form. Growth of s.c. tumors was monitored by caliper measurements of the hindleg at the site of tumor cell inoculation; growth of ascitic tumors was followed by electrophoretic determination in plasma of the tumor associated protein IgG2a.kappa., M component. Adult mice were treated with 6-OHDA or DSP-4 6 h prior to tumor cell implantation; newborn mice were treated with anti-NGF and tumor cells were given 9 wk later. Both chemical- and immunosympathectomy significantly altered the growth pattern of solid and ascitic tumors (P < 0.0001). The effect of sympathectomy on the growth of solid tumors was most pronounced during the early phase of tumor growth. The effect of each drug treatment on tumor growth was not due to direct cytotoxic actions of the agents employed on tumor cells but the result of impairment of sympathetic functions. The sympathetic nervous system may play a role in tumor growth.

Accession: 006555705

Download citation: RISBibTeXText

PMID: 3926856

DOI: 10.1016/0165-1838(85)90031-1

Download PDF Full Text: Sympathectomy inhibits growth of a murine plasmacytoma tumor

Related references

A monoclonal antibody specific for the murine IL-6-receptor inhibits the growth of a mouse plasmacytoma in vivo. Current Topics in Microbiology and Immunology 166: 43-46, 1990

Tumor necrosis factor and interleukin 1 can act as essential growth factors in a murine plasmacytoma line. Lymphokine Research 7(2): 99-106, 1988

The role of plasmacytoma growth factor in the in vitro responses of murine plasmacytoma cells. Annals of the New York Academy of Sciences 557: 200-205, 1989

Regulation of murine plasmacytoma transferrin receptor expression and G1 traversal by plasmacytoma cell growth factor. Journal of Cellular Physiology 135(3): 495-501, 1988

The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction. Journal of Immunology 118(4): 1441-1448, 1977

Effects of host age and 6 hydroxydopamine chemical sympathectomy on c 1300 murine neuroblastoma tumor growth in vivo. Federation Proceedings 44(5): 1385, 1985

A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Research 67(5): 2351-2359, 2007

Gan-Lu-Yin Inhibits Proliferation and Migration of Murine WEHI-3 Leukemia Cells and Tumor Growth in BALB/C Allograft Tumor Model. Evidence-Based Complementary and Alternative Medicine 2013: 684071-684071, 2013

Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model. Cytokine 49(3): 287-293, 2010

Modulation of in situ murine neuroblastoma tumor growth by the adrenergic nervous system differential response of clonal cell lines to chemical sympathectomy. Life Sciences 47(24): 2251-2260, 1990

Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 100(9): 3361-3368, 2002

G-M3 inhibits murine MBT-2 tumor invasion and growth. International Journal of Oncology 8(4): 809-813, 1996

Prostaglandins, but not tumor-derived IL-10, shut down concomitant tumor-specific CTL responses during murine plasmacytoma progression. International Journal of Cancer 91(5): 705-712, 1 March, 2001